Open Angle Glaucoma Segment, by Indication to Account Larger Share in Glaucoma Therapeutics Market during 2023-2031

According to our latest study on "Glaucoma Therapeutics Market Forecast to 2031 -Global Analysis - Drug Class, Indication, and Distribution Channel," the market was valued at US$ 6.24 billion in 2023 and is projected to reach US$ 8.02 billion by 2031; it is estimated to record a CAGR of 3.2% during 2023-2031. The report highlights the key factors driving the Glaucoma Therapeutics market growth and prominent players with their developments in the market.

The Glaucoma Therapeutics market analysis has been carried out by considering the following segments: drug class, indication, and distribution channel, and geography.

Based on drug class, the glaucoma therapeutics market is segmented into beta blockers, alpha-adrenergic agonists, prostaglandin analogs, carbonic anhydrase inhibitors, combination drugs, and others.

By indication, the market is segmented into open angle glaucoma, angle closure glaucoma, and others. The open-angle glaucoma segment held the largest glaucoma therapeutics market share in 2023 and is projected to register the highest CAGR from 2023 to 2031.

By distribution channel, the market is segmented into hospital pharmacy, retail pharmacy, and online pharmacy. The hospital pharmacy segment dominated the market in 2023.

The scope of the Glaucoma Therapeutics market report covers North America (the US, Canada, and Mexico), Europe (Spain, the UK, Germany, France, Italy, and the Rest of Europe), Asia Pacific (South Korea, China, Japan, India, Australia, and the Rest of Asia Pacific), Middle East & Africa (South Africa, Saudi Arabia, the UAE, and the Rest of Middle East & Africa), and South & Central America (Brazil, Argentina, and the Rest of South & Central America). North America is the biggest contributor to the global Glaucoma Therapeutics market. Asia Pacific is predicted to show the highest CAGR in the market during 2023-2031. Propelling number of glaucoma cases among the American population are a major driver of the glaucoma therapeutics market in North America.

Inoteck Pharmaceuticals; Merck & Co., Inc.; Novartis AG; Pfizer Inc.; Santen Pharmaceutical Co., Ltd.; Teva Pharmaceutical Industries Ltd; Takeda Pharmaceutical Company; AstraZeneca PLC; AERIE Pharmaceuticals, Inc.; Alcon and Cipla Inc are among the leading companies operating in the global Glaucoma Therapeutics market.

Companies operating in the glaucoma therapeutics market adopt various organic and inorganic strategies. Organic strategies mainly include product launches and product approvals. Acquisitions, collaborations, and partnerships are among the inorganic growth strategies witnessed in the glaucoma therapeutics market. These growth strategies allow the market players to expand their businesses and enhance their geographic presence, thereby contributing to the overall market growth. Further, acquisition and partnership strategies help them strengthen their customer base and expand their product portfolios.
Contact Us
Contact Person: Sameer Joshi
Phone: +1-646-491-9876
Email Id: sales@premiummarketinsights.com